Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 8;15(3):320.
doi: 10.3390/ph15030320.

Small Molecule Induced FLT3 Degradation

Sun-Young Han  1
Affiliations
Review

Small Molecule Induced FLT3 Degradation

Sun-Young Han. Pharmaceuticals (Basel). .

Abstract

Target protein degrader is a new paradigm in the small molecule drug discovery field and relates to the term 'event-driven pharmacology'. Fms-like tyrosine kinase 3 (FLT3) is a significant target for treating acute myeloid leukemia (AML). A few FLT3 kinase inhibitors are currently used in the clinic for AML patients. However, resistance to current FLT3 inhibitors has emerged, and strategies to overcome this resistance are required. Small molecules downregulating FLT3 protein level are reported, exhibiting antileukemic effects against AML cell lines. Small molecules with various mechanisms such as Hsp90 inhibition, proteasome inhibition, RET inhibition, and USP10 inhibition are explained. In addition, reports of FLT3 as a client of Hsp90, current knowledge of the ubiquitin proteasome system for FLT3 degradation, the relationship with FLT3 phosphorylation status and susceptibility of FLT3 degradation are discussed.

Keywords: fms-like tyrosine kinase 3; heat shock protein 90; target protein degrader; ubiquitin proteasome system.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
FLT3 degradation by small molecules.
See this image and copyright information in PMC

References

    1. Lai A.C., Crews C.M. Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov. 2017;16:101–114. doi: 10.1038/nrd.2016.211. - DOI - PMC - PubMed
    1. Dale B., Cheng M., Park K.-S., Kaniskan H., Xiong Y., Jin J. Advancing targeted protein degradation for cancer therapy. Nat. Cancer. 2021;21:638–654. doi: 10.1038/s41568-021-00365-x. - DOI - PMC - PubMed
    1. Newell L.F., Cook R.J. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026. doi: 10.1136/bmj.n2026. - DOI - PubMed
    1. DiPiro J.T. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. McGraw-Hill Medical; New York, NY, USA: 2016.
    1. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Cancer. 2003;3:650–665. doi: 10.1038/nrc1169. - DOI - PubMed

LinkOut - more resources